No Data
ATyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro
Express News | HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)
Strong Buy Rating for ATyr Pharma as Efzofitimod Shows Promise and Financial Stability
Express News | ATyr Pharma Inc: Believes Cash Runway to Be Sufficient to Fund Operations Through Filing of Bla for Efzofitimod in Pulmonary Sarcoidosis
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
04:00 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000